BI 10773 Cardiovascular Outcomes Trial in Type 2 Diabetes Mellitus Patients - Trial SLCTR_2011_008
Access comprehensive clinical trial information for SLCTR_2011_008 through Pure Global AI's free database. This Phase 3 trial is sponsored by Boehringer Ingelheim India Pvt Ltd and is currently status unknown. The study focuses on Diabetes Mellitus, Type 2.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
SLCTR_2011_008
Phase 3
Trial Details
Sri Lanka Clinical Trials Registry • SLCTR_2011_008
BI 10773 Cardiovascular Outcomes Trial in Type 2 Diabetes Mellitus Patients
A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovas
Study Focus
Interventional
Sponsor & Location
Boehringer Ingelheim India Pvt Ltd
Argentina, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Denmark, France, Georgia, Greece, Hu
Timeline & Enrollment
Phase 3
N/A
N/A
ICD-10 Classifications
Type 2 diabetes mellitus
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications
Data Source
Sri Lanka Clinical Trials Registry
SLCTR_2011_008
Non-Device Trial